MSU researchers find early, promising glioblastoma treatment
A team of Michigan State University scientists has unveiled a potential game-changer in the fight against glioblastoma, the most common and currently incurable form of brain cancer.
Their weapon of choice? A drug-like compound named Ogremorphin, or OGM. In laboratory experiments, OGM showed a remarkable ability to kill glioblastoma cells while leaving normal cells unharmed.
A Spartan Changing the Way We Fight Cancer
Carolina de Aguiar Ferreira couldn’t do what she does anywhere else.
The assistant professor has the resources at Michigan State University to precisely target cancer cells with diagnostics and therapies using radioisotopes produced by what is designed to be the world's most powerful heavy-ion accelerator.
When considering where to pursue her career, she knew MSU provided the perfect environment.
Henry Ford + MSU Select Grant Recipients for the 2023 Cancer Seed Funding Program
Henry Ford Health + Michigan State University Health Sciences has announced its integration grant recipients for the 2023 Cancer Seed Funding Program. This year’s program funded four cancer research grants of up to $75,000 each. These four grants follow the funding of 20 pilot grants of $25,000 each in July 2023.
Henry Ford + MSU Cancer Research Symposium Inspires and Builds Collaboration
On November 9 and 10, over 225 Henry Ford Health + Michigan State University Health Sciences researchers gathered on the MSU campus for the 3rd Annual Henry Ford + MSU Cancer Research Symposium.
The two-day event focused on advancing research through innovation and collaboration. With more than 30 research presentations from Henry Ford and MSU, topics ranged from experimental and clinical therapeutics to opportunities for clinical trials and interventional studies.